Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 20

22:19 EDT 22nd September 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 7,700+

Probably Relevant

28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research

Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.


Cardiol Therapeutics Closes CDN$10.5 Million Private Placement; #Nanotherapeutics

Toronto, Ontario - May 24, 2018 (Newsfile Corp.) (Investorideas.com Newswire) Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart

iTeos Therapeutics Closes on $75 Million Series B Financing

Belgium-based iTeos Therapeutics SA completed an oversubscribed Series B financing worth $75 million.


Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.

Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.

Sangamo to acquire TxCell for €65.8mm

Sangamo Therapeutics Inc. will pay €65.8mm ($77mm; €2.58 per share, a 175% premium) to acquire privately held T-cell immu...

Global Outlook for the Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022 – Rising Number of Patients Opting for Chemotherapy – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022. The report has been prepared based on an … Continue reading → Cet article Globa...

Orchard Therapeutics receives Rare Pediatric Disease Designation from FDA

Orchard Therapeutics, a commercial stage company, has been granted a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its gene therapy candidate, OTL-200, for the treatment of patients with MLD

Sarepta Therapeutics-Aktie: weitere Outperformance trotz Kurssteigerungen!

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse des Analysten Brian Abrahams von RBC Capital Markets: Analyst Brian Abrahams vom Investmenthaus RBC Capital Markets bestätigt laut ...

Acorda Therapeutics Has One Bad Week With Loss of Patents and Delayed FDA Review

Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA's decision to delay a ruling for its Parkinson’s disease treatment.

Syndesi Therapeutics launches with €17mm Series A

Syndesi Therapeutics SA (cognitive disorders) has launched with a €17mm ($21mm) Series A round from an investor syndicate c...

Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies

Unum Therapeutics is the latest biotechnology company to take the plunge into the public markets, raising $69.2 million that it plans to use to fund more clinical tests of its experimental cancer treatments. The Cambridge, MA, company priced its initial public stock offering of 5.77 million shares at $12 each, which was on the low […]

Phanes Therapeutics selects CrownBio to advance oncology drug pipeline

Global drug discovery and development services company, Crown Bioscience, has been selected as a strategic partner by Phanes Therapeutics to accelerate the discovery and development of novel oncology agents.

Digital therapeutics company Click brings in $17mm in Sanofi Ventures-led round

Click Therapeutics Inc. (developing software as prescription medicines) raised $17mm in an undisclosed round led by Sanofi Ve...

Digital therapeutics company Click brings in $17mm through Sanofi Ventures-led round

Click Therapeutics Inc. (developing software as prescription medicines) raised $17mm in an undisclosed round led by Sanofi Ve...

Antisense Therapeutics Limited: First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy

MELBOURNE, AUSTRALIA / ACCESSWIRE / August 29, 2018 / Antisense Therapeutics (ASX: ANP) today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL...

Eidos Therapeutics Closes on Series B Round Worth $64M

Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.

Therapeutics and collaboration in the spotlight at Technology Showcase

This year’s Technology Showcase, held on 13 June at Oxford’s Saïd Business School, attracted a host of leading academics, clinicians and investors to discuss the most exciting commercial opportunities and projects in the field of Therapeutics, Small Molecules and Biologics. The event, which was attended by around 200 people, was organised by the NIHR Oxford BRC, ... Read more

Dr. Bob Raffa Joins Bridge Therapeutics' Scientific Advisory Board Bring Decades of Research ...

BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. Read more...

Beleaguered Regulus Therapeutics Slashes 60 Percent of Workforce in New Corporate Restructuring

Shares of Regulus Therapeutics saw something of a slight rally on Monday following a post-Independence Day corporate restructuring announcement that included the termination of 60 percent of its workforce, which caused a massive stock plummet.

FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

The U.S. Food and Drug Administration declined to approve Pain Therapeutics Inc's abuse-deterrent opioid treatment Remoxy for the fourth time, sending the company's shares down 35 percent to a record low.

Initial public offering nets $93mm for Magenta Therapeutics

Magenta Therapeutics Inc. (curative stem cell transplantation) netted $93mm through its initial public offering of 6.67mm com...

Cardiol Therapeutics Closes CDN$10.5 Million Private Placement

Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the successful closing of a brokered private placement (the "Private Placement") of approximately CDN$10.5 million princi...

Small-Cap Snapshot: Pain Therapeutics shares rally after defying FDA rejection of lead drug

Small cap names on the move today are: Pain Therapeutics Inc (NASDAQ:PTIE), Casa Systems Inc's (NASDAQ:CASA), PetlQ Inc (NASDAQ:PETQ), Sigma Designs Inc (NASDAQ:SIGM). 

Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update

Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced financial and operating results for the first quarter ended March 31, 2018, and provided a corporate update. As quoted in the press release: “Since our acquisition of SynGen in July of last year, we have made substantial progress … Continued The...

Protagonist Therapeutics nets $21.8mm via PIPE

Peptide therapies developer Protagonist Therapeutics Inc. netted $21.8mm through the sale of 2.75mm common shares at $8 each ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks